Loading…
APO-QUINAPRIL / HCTZ is a brand name for Quinapril, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ....................................................................................3 CONTRAINDICATIONS .........................................................................................................3 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
, Monitoring and Laboratory Tests, Serum Electrolytes, ADVERSE REACTIONS, and DRUG INTERACTIONS, Agents Increasing Serum Potassium, Trimethoprim-containing products). The addition of a potassium-sparing diuretic to APO- QUINAPRIL / HCTZ TABLETS, which contains a diuretic, is not recommended.
Hydrochlorothiazide:
Treatment with thiazide diuretics has been associated with hypokalemia. Hypokalemia can also sensitize or exaggerate the response of the heart to the toxic effects of digitalis. g. aminoglycoside antibiotics, cisplatin, foscarnet, amphotericin B and loop diuretics (furosemide)).
Quinapril/Hydrochlorothiazide:
The opposite effects of hydrochlorothiazide and quinapril on serum potassium may approximately balance each other in many patients so that no net effect will be seen. In other patients, one or the other effect may be dominant.
Other electrolytes imbalances Hydrochlorothiazide:
In addition to hypokalemia, treatment with thiazide diuretics has also been associated with hyponatremia and hypochloremic alkalosis. These disturbances have sometimes been manifest as one or more of the following: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, nausea, confusion, seizures and vomiting.
g. in liver disease or renal disease). Dilutional hyponatremia may occur in edematous patients, especially in hot weather; appropriate therapy is water restriction rather than administration of salt, except when the hyponatremia is life threatening.
In actual salt depletion, replacement of salt is the therapy of choice. Thiazides may decrease calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.
Marked hypercalcemia may be evidence of hidden hypoparathyroidism. In a few patients on prolonged thiazide therapy, pathological changes in the parathyroid gland have been observed, with hypercalcemia and hypophosphatemia. More serious complications of hyperparathyroidism (renal lithiasis, bone resorption, and peptic ulceration) have not been seen.
Thiazides should be discontinued before performing tests for parathyroid function. Thiazides increase the urinary excretion of magnesium, and hypomagnesaemia may result.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Quinapril in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Hypoglycemia/Hyperglycemia and Diabetes Quinapril:
ACE inhibitors may reduce insulin resistance and may lead to hypoglycemia in diabetic patients on insulin or oral hypoglycemic agents; closer monitoring of diabetic patients may be required. APO-QUINAPRIL / HCTZ TABLETS (Quinapril and Hydrochlorothiazide Tablets) Page 8 of 51 Hydrochlorothiazide: Thiazide-induced hyperglycemia may compromise blood sugar control.
Depletion of serum potassium augments glucose intolerance. g. insulin, oral hypoglycemic agents, sitagliptin). Overt diabetes may be precipitated in susceptible individuals. Other metabolic parameters Hyperuricemia may occur, or acute hyperuricemia may be precipitated, in certain patients receiving thiazide therapy.
Increase in cholesterol, triglyceride and glucose levels may be associated with thiazide diuretic therapy. Thiazides may decrease serum PBI levels without signs of thyroid disturbance. Hematologic Neutropenia/Agranulocytosis Agranulocytosis and bone marrow depression have been caused by ACE inhibitors.
Agranulocytosis did occur during quinapril treatment in one patient with a history of neutropenia during previous captopril therapy. Periodic monitoring of white blood cell counts should be considered, especially in patients with collagen vascular disease and/or renal disease.
Hepatic Impairment of Liver Function Hepatitis (hepatocellular and/or cholestatic), elevations of liver enzymes and/or serum bilirubin have occurred during therapy with other ACE inhibitors in patients with or without pre-existing liver abnormalities.
In most cases the changes were reversed on discontinuation of the drug. Elevations of liver enzymes and/or serum bilirubin have been reported for quinapril and hydrochlorothiazide tablets (see ADVERSE REACTIONS). Should the patient receiving APO- QUINAPRIL / HCTZ TABLETS experience any unexplained symptoms particularly during the first weeks or months of treatment, it is recommended that a full set of liver function tests and any other necessary investigation be carried out.
Discontinuation of APO-QUINAPRIL / HCTZ TABLETS should be considered when appropriate. There are no adequate studies in patients with cirrhosis and/or liver dysfunction. APO-QUINAPRIL / HCTZ TABLETS should be used with particular caution in patients with pre-existing liver abnormalities.
In such patients baseline liver function tests should be obtained before administration of the drug and close monitoring of response and metabolic effects should apply. APO-QUINAPRIL / HCTZ TABLETS (Quinapril and Hydrochlorothiazide Tablets) Page 9 of 51 Patients with Impaired Liver Function APO-QUINAPRIL / HCTZ TABLETS should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Also, since the metabolism of quinapril to quinaprilat is normally dependent upon hepatic esterase, patients with impaired liver […]